drugset / Trial / NCT03993964
Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study was to observe the efficacy and safety of treatment with pyrotinib and CDK4/6 inhibitor SHR6390 for HER2-positive metastatic breast cancer.
Timeline
- Start
- 2019-08-15
- Primary completion
- 2020-10-30
- Completion
- 2021-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | 125 mg | — |
| Subject | Pyrotinib | Small molecule | 400 mg | — |